The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people who already have one, a new study shows. Semaglutide (also known as Ozempic) ...

Interest in GLP-1s for addiction has grown in the past decade, as some people prescribed them for diabetes or weight loss ...

A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin ...

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction - and help people who already have one, a ...

For the first time in several years, two contested applications for preliminary injunctions (PIs) have been granted by the Federal Court in Australian pharmaceutical patent cases.

For many people diagnosed with Type 2 diabetes, the first medicine doctors prescribe is metformin. Metformin has been used for decades and is considered a reliable and effective treatment. It works ...

Navigating drug coverage demands brain power in our DIY retirement system, and it isn’t getting any easier. While President Donald Trump has launched TrumpRx and other initiatives to lower costs, ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

Q: I’m taking a GLP-1 to help me control my blood sugar and lose weight. But the cost and side effects of having to do resistance exercise make it difficult ...